HL 1225

Drug Profile

HL 1225

Alternative Names: HL1225

Latest Information Update: 03 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Handok Pharmaceuticals
  • Developer Handok Inc
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 03 Oct 2013 Discontinued - Phase-II for Diabetes mellitus in South Korea (unspecified route)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc.
  • 22 Jun 2011 HL 1225 is available for partnering as of 22 Jun 2011. http://www.handok.co.kr
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top